Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06491927 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long Term Follow-up for RGX-202

StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv4
  2. Enrollment target: 19 to 66 Study sites: 2 to 5 · Secondary endpoints: 1 to 9 · Study description expanded, about 1 wordv3 Show 3 more changesShow less
    • Study sites: 2 to 5
    • Secondary endpoints: 1 to 9
    • Study description expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 3 to 2v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RGX-202-5101 is a long-term follow up study that evaluates the long-term safety and efficacy of RGX-202 in participants who have received RGX-202 (an investigative gene therapy designed to deliver a transgene for novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain) in a separate parent study.
Trial Details
NCT Number NCT06491927
Lead Sponsor REGENXBIO Inc.
Conditions Duchenne Muscular Dystrophy
Enrollment 66 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov